<DOC>
	<DOCNO>NCT00108186</DOCNO>
	<brief_summary>This proposal evaluate cyclooxygenase 2 ( COX-2 ) inhibition mean decrease T regulatory cell activity thus augment immune response lung cancer . The broad goal focus understand COX-2 expression regulate malignant phenotype non small cell lung cancer effort foster inform approach use COX-2 inhibitor prevention therapy lung cancer .</brief_summary>
	<brief_title>Celecoxib Treatment Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Pathologically confirm surgically resectable non small cell lung cancer subject must ineligible refuse , neoadjuvant therapy Hypersensitivity celecoxib NSAIDs , previous history GI bleeding ulceration , chronic concurrent use steroid renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>cyclooxygenase 2</keyword>
	<keyword>lung cancer</keyword>
	<keyword>lymphocyte</keyword>
	<keyword>non small cell</keyword>
	<keyword>therapeutic</keyword>
</DOC>